
export const hypertrophicCardiomyopathyDiagnosticInvestigations = {
  title: "Diagnostic Procedures",
  sections: [
    {
      title: "Evaluation of unexplained syncope",
      evidenceLevel: "B",
      guidelines: [
        {
          organization: "ESC 2018",
          recommendation: "Obtain 2D and Doppler echocardiography during exercise in the standing, sitting, or semi-supine position to detect provocable LVOTO in patients with HCM, history of syncope, and a resting or provoked peak instantaneous LVOT gradient < 50 mmHg."
        },
        {
          organization: "ESC 2014", 
          recommendation: "Obtain a 12-lead ECG, an upright exercise test, resting and exercise 2D and Doppler echocardiography, and 48-hour ambulatory ECG monitoring in patients with unexplained syncope."
        }
      ]
    },
    {
      title: "Coronary angiography",
      evidenceLevel: "B",
      guidelines: [
        {
          organization: "ACC/AHA/AMSSM/SCMR 2024",
          recommendations: [
            "Obtain coronary angiography (CT or invasive) in patients with HCM having symptoms or evidence of myocardial ischemia.",
            "Obtain coronary angiography (CT or invasive) before surgical myectomy in patients with HCM at risk of coronary atherosclerosis."
          ]
        },
        {
          organization: "ESC 2014",
          recommendation: "Obtain invasive coronary angiography in adult survivors of cardiac arrest, in patients with sustained ventricular tachyarrhythmia, and in patients with severe stable angina."
        }
      ]
    },
    {
      title: "Cardiac catheterization",
      evidenceLevel: "B",
      guidelines: [
        {
          organization: "ACC/AHA/AMSSM/SCMR 2024",
          recommendation: "Perform cardiac catheterization for invasive hemodynamic assessment in patients with symptomatic HCM if there is uncertainty regarding the presence or severity of LVOTO on noninvasive imaging."
        },
        {
          organization: "ESC 2023",
          recommendation: "Consider performing left and right heart catheterization to assess the severity of LVOTO and to measure LV filling pressures in symptomatic patients with HCM if noninvasive cardiac imaging is inconclusive.",
          evidenceLevel: "C"
        }
      ]
    },
    {
      title: "Electrophysiological study",
      guidelines: [
        {
          organization: "ACC/AHA/HRS 2019",
          recommendation: "Consider obtaining an electrophysiological study for the evaluation of ventriculoatrial conduction at the time of alcohol septal ablation to identify the future risk of AV block.",
          evidenceLevel: "C"
        },
        {
          organization: "ACC/AHA/HRS 2018",
          recommendation: "Do not obtain an invasive electrophysiological study with programmed ventricular stimulation for risk stratification in patients with HCM.",
          evidenceLevel: "D"
        },
        {
          organization: "ESC 2014",
          recommendations: [
            "Obtain an invasive electrophysiological study in patients with documented persistent or recurrent SVT (atrial flutter, AT, atrioventricular nodal reentry tachycardia, accessory atrioventricular pathway-mediated tachycardias) and in patients with ventricular preexcitation, in order to identify and treat an ablatable substrate.",
            "Obtain an invasive electrophysiological study to identify and treat any ablatable arrhythmia substrate in patients with ICDs and inappropriate shocks due to regular SVTs."
          ],
          evidenceLevel: "B"
        }
      ]
    },
    {
      title: "Laboratory tests",
      evidenceLevel: "B",
      guidelines: [
        {
          organization: "ESC 2023",
          recommendations: [
            "Obtain routine first-line laboratory tests in all patients with suspected or confirmed cardiomyopathy to evaluate etiology, assess disease severity, and aid in detecting extracardiac manifestations and assessing secondary organ dysfunction.",
            "Consider obtaining additional tests in patients with cardiomyopathy and extracardiac features to aid in detecting metabolic and syndromic causes following specialist evaluation."
          ]
        }
      ]
    },
    {
      title: "Genetic testing",
      evidenceLevel: "B",
      guidelines: [
        {
          organization: "ACC/AHA/AMSSM/SCMR 2024",
          recommendations: [
            "Obtain genetic testing in patients with HCM to elucidate the genetic basis to facilitate the identification of family members at risk for developing HCM (cascade testing).",
            "Obtain genetic testing for HCM and other genetic causes of unexplained cardiac hypertrophy (HCM phenocopies) in patients with an atypical clinical presentation of HCM or when another genetic condition is suspected to be the cause.",
            "Include genes with strong evidence of being disease-causing in HCM in the initial tier of genes tested in a proband with HCM.",
            "Obtain serial re-evaluation of the clinical significance of identified variants to assess for variant reclassification, which may impact diagnosis and cascade genetic testing in family members."
          ]
        },
        {
          organization: "ESC 2023",
          recommendations: [
            "Obtain genetic testing in patients fulfilling diagnostic criteria for cardiomyopathy in cases where it enables diagnosis, prognostication, therapeutic stratification, or reproductive management of the patient or where it enables cascade genetic evaluation of their relatives otherwise eligible for enrollment into long-term surveillance.",
            "Obtain genetic testing for a deceased individual identified to have cardiomyopathy at post-mortem if a genetic diagnosis would facilitate the management of surviving relatives."
          ]
        }
      ]
    },
    {
      title: "Endomyocardial biopsy",
      evidenceLevel: "C",
      guidelines: [
        {
          organization: "ESC 2023",
          recommendation: "Consider performing an endomyocardial biopsy in patients with suspected cardiomyopathy to aid in diagnosis and management when the results of other clinical investigations suggest myocardial inflammation, infiltration, or storage that cannot be identified by other means."
        }
      ]
    }
  ]
}; 